Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MoST Substudy 1: Single arm, open label, signal seeking, phase Ib/IIa trial of the CDK4/6 inhibitor palbociclib in patients with tumours with amplified D-type cyclins or CDK4 or inactivation of CDKN2A

Next Previous
X
Search
Trial Profile

MoST Substudy 1: Single arm, open label, signal seeking, phase Ib/IIa trial of the CDK4/6 inhibitor palbociclib in patients with tumours with amplified D-type cyclins or CDK4 or inactivation of CDKN2A

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms MoST Substudy 1

    • Most Recent Events

    • 31 Aug 2023 Results from DRUP and Australian MoST , for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib published in the International Journal of Cancer
    • 06 Jun 2023 Results (n=139) assessing efficacy and safety of of palbociclib and ribociclib monotherapy in advanced cancers in the Dutch DRUP and Australian MoST trials, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 17 Feb 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top